Posts Tagged ‘glp1-PSM-content’
Key takeaways from PSM’s Axios event: Examining risk and regulation in the compounded GLP-1 landscape
SAFE Drugs Act sponsor Rep. Rudy Yakym (R-IN), Rep. Nikki Budzinski (D-IL), leading obesity medicine specialist Dr. Scott Kahan, and PSM Executive Director Shabbir Imber Safdar. delivered a clear message: Compounded substances are not the same as FDA-approved medications, and treating them as such undermines patients’ safety.
[...]PSM’s action plan to protect patients from unapproved compounded GLP-1s
Read our roadmap to uphold the gold standard system that protects Americans from untested and unsafe medicines.
[...]PSM urges the House Energy & Commerce Committee to support the SAFE Drugs Act of 2025
PSM wrote the House Energy & Commerce Committee in support of the Safeguarding Americans from Fraudulent and Experimental (SAFE) Drugs Act, to help protect the American drug supply from unsafely compounded medication.
[...]FDA Alert: More Counterfeit Ozempic found in U.S. Supply Chain
The FDA and Novo Nordisk are warning the public about counterfeit Ozempic injections circulating in the legitimate U.S. drug supply chain. The FDA announced the seizure of multiple batches of counterfeit Ozempic 1 mg injections, labeled with lot number PAR1229, on December 5, 2025. Their contents and safety are unverified and pose serious health risks.
[...]PSM signs letter of support for changes to Mississippi’s compounding pharmacy guidelines
The proposed updates aim to help address safety concerns created by pharmacies reselling compounded sterile drugs purchased from outsourcing facilities.
[...]What is a 503B outsourcing facility, and why are so many of them uninspected by FDA?
503B outsourcing facilities make our drug supply more resilient, but 81% of 503Bs newly registered since June 2021 have never been inspected by FDA staff. Learn why we recommend changes to this important program.
[...]FDA Alert: Counterfeit Ozempic found in U.S. Supply Chain
The FDA and Novo Nordisk are warning the public about counterfeit Ozempic injections circulating in the U.S. drug supply chain. The falsified products, labeled with lot number PAR0362 and serial numbers beginning with 51746517, were seized by the FDA on April 9, 2025. Their contents and safety are unverified and pose serious health risks.
[...]Handout: Illegal ingredients linked to knockoff weight loss drugs pouring in from foreign sources
Compounded versions of GLP-1 injectable treatments for diabetes and obesity have surged in popularity despite a lack the safety and efficacy assurances. The FDA has warned that these knockoff versions sometimes contain illicit semaglutide or tirzepatide—the active pharmaceutical ingredients (APIs) in weight loss drugs. Working with George Karavetsos, former director of FDA’s Office of Criminal…
[...]New report reveals illegal ingredients for knockoff weight loss drugs flooding into U.S. from foreign sources, endangering patient safety
The Partnership for Safe Medicines today released a new report that found suspicious, unauthorized, and illegal ingredients for popular diabetes and obesity injectables (commonly known as weight loss drugs) are flooding into the U.S. from foreign sources despite U.S. laws forbidding them from coming through the border.
[...]PSM applauds Arkansas Board of Pharmacy for protecting patients
The Partnership for Safe Medicines applauds the Arkansas State Board of Pharmacy for utilizing new product verification technology for identifying illegitimate Ozempic quarantined by a pharmacy this week.
[...]